At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Ixazomib Oral Capsuledrug
Likely dose
Ixazomib Oral Capsule 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ixazomib for Desensitization in Kidney Transplantation
In Brief
A Phase 2 clinical trial evaluating Ixazomib Oral Capsule for Kidney Diseases and End Stage Renal Disease. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this research study is to find out how well ixazomib (the study drug) works to desensitize highly sensitized kidney transplant recipients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Diseases, End Stage Renal Disease
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartSep 2017
Primary CompletionApr 2021
TodayJul 2026
First PostedJul 11, 2017
Enrollment StartSep 15, 2017
Primary CompletionApr 16, 2021
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.0 years ago
Interventions
Ixazomib Oral Capsuledrug
Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle. Patients will take ixazomib and dexamethasone for twelve (12) 28-day cycles.